RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program
Dong, O. M., Bates, J., Chanfreau-coffinier, C., Naglich, M., Kelley, M. J., Meyer, L. J., Icardi, M., Vassy, J. L., Sriram, P., Heise, C. W., Rivas, S., Ribeiro, M., Jacobitz, R., Rozelle, S., Chapman, J. G., & Voora, D. (2021). Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program. Pharmacogenomics, 22(3), 137-144. https://doi.org/10.2217/pgs-2020-0173
In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.
Tweetable abstract: Launched in March 2019 as a partnership between the VA and Sanford Health, the VA PHASER program is a national clinical program that offers free, multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 VA sites over 5 years.